KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $246.3 million.

  • Pacira BioSciences' Cash & Current Investments fell 45.72% to $246.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 14.22%. This contributed to the annual value of $484.6 million for FY2024, which is 73.96% up from last year.
  • As of Q3 2025, Pacira BioSciences' Cash & Current Investments stood at $246.3 million, which was down 44.75% from $445.9 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Cash & Current Investments registered a high of $693.9 million during Q3 2021, and its lowest value of $174.0 million during Q1 2023.
  • Over the past 3 years, Pacira BioSciences' median Cash & Current Investments value was $325.9 million (recorded in 2024), while the average stood at $342.1 million.
  • In the last 5 years, Pacira BioSciences' Cash & Current Investments spiked by 97.86% in 2021 and then slumped by 61.52% in 2023.
  • Pacira BioSciences' Cash & Current Investments (Quarterly) stood at $656.4 million in 2021, then plummeted by 56.03% to $288.7 million in 2022, then fell by 3.49% to $278.6 million in 2023, then skyrocketed by 73.96% to $484.6 million in 2024, then slumped by 45.72% to $246.3 million in 2025.
  • Its last three reported values are $246.3 million in Q3 2025, $445.9 million for Q2 2025, and $493.6 million during Q1 2025.